Graves' disease and other forms of hyperthyroidism in infants and children

Current Opinion in Endocrinology and Diabetes

Volumn 3, Issue 2, 1996, Pages 101-109

  LaFranchi, Stephen ^a   Mandel, Scott ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0005018870     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-199604000-00005     Document Type: Article

References (69)

1. Ramsay I, Kaur S, Krassas G: Thyrotoxicosis in pregnancy: results of treatment by antithyroid drugs combined with T4. Clin Endocrinol 1983, 18:73-85.
2. Dirmikis SM, Munro DS: Placental transmission of thyroid-stimulating Immunoglobulins. BMJ 1975, 2:665-666.
3. McKenzie JM: Neonatal Graves' disease. J Clin Endocrinol Metab 1964, 24:660-668.
4. McKenzie JM, Zakarija M: Fetal and neonatal hyperthyroidism and hypothyroidism due to maternal TSH receptor antibodies. Thyroid 1992, 2:155-159.
5. 2. J Pediatr 1978, 93:118-120.
6. Sunshine P, Kusumoto H, Kriss JP: Survival time of circulating long- acting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder. Pediatrics 1965, 36:869-876.
7. Matsura N, Konishi J, Fujieda K, Kasagi K, Iida Y, Hagisawa M, Fujimoto S, Fukushi M, Takasugi N: TSH-receptor antibodies in mothers with Graves' disease and outcome in their offspring. Lancet 1988, 1:1417.
8. Munro DS, Dirmikis SM, Humphries H, Smith T: The role of thyroid stimulating immunoglobulins of Graves' disease in neonatal thyrotoxicosis. Br J Obstet Gynaecol 1978, 85:837-843.
9. Tamaki H, Amino N, Aozasa M, Mori M, Iwatani Y, Tachi J, Nose D, Tanizawe D, Miyai K: Universal predictive criteria for neonatal overt thyrotoxicosis requiring treatment Am J Perionatal 1988, 5:152-158.
10. Zakarija M, McKenzie JM: Pregnancy-associated changes in the thyroid-stimulating antibody of Graves' disease and the relationship to neonatal hyperthyroidism. J Clin Endocrinol Metab 1983, 57:1036-1040.
11. Hollingsworth DR, Mabry CC: Congenital Graves' disease: four familial cases with long-term follow-up and perspective. Am J Dis Child 1976, 130:148-155.
12. Kopp P, Van Sande J, Parma J, Duprez L, Gerber H, Joss E, Jameson JL, Dumont JE, Vassart G: Brief report: congenital hyperthyroidism caused by a mutation in the thyrotropin-receptor gene. N Engl J Med 1995, 332:150-154. Important paper detailing the molecular basis for persistent congenital hyperthyroidism that is shown to be due to a single amino acid substitution in the thyrotropin receptor gene resulting in constitutive activation of the receptor.
13. Duprez L, Parma J, Van Sande J, Allgeier A, Leclere J, Schvartz C, Delisle M-J, Decoulx M, Ogiazzi J, Dumont J, Vassart G: Germline mutations in the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism. Nat Genet 1994, 7:396-401. Activating mutations are demonstrated in the germline in two families with nonautoimmune hyperthyroidism.
14. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G: Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 1993, 365:649-651.
15. Bryant WP, Zimmerman D: Iodine-induced hyperthyroidism in a newborn. Pediatrics 1995, 95:434-436. Case report of clinically significant iodine-induced hyperthyroidism in a newborn.
16. Magee LA, Downar E, Sermer M, Boulton BC, Allen LC, Koren G: Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol 1995, 172:1307-1311.
17. Farrehi C: Accelerated maturity in fetal thyrotoxicosis. Clin Pediatr 1968, 7:134-137.
18. Kopelman AE: Delayed cerebral development in twins with congenital hyperthyroidism. Am J Dis Child 1983, 137:842-845.
19. Zakarija M, McKenzie JM, Hoffman WH: Prediction and therapy of intrauterine and late-onset neonatal hyperthyroidism. J Clin Endocrinol Metab 1986, 62:368-371.
20. Zakarija M, De Forteza R, McKenzie JM, Ghandur-Mnaymneh L: Characteristics and clinical correlates of a novel thyroid-stimulating autoantibody. Autoimmunity 1994, 19:31-37.
21. Cove DH, Johnston P: Fetal hyperthyroidism: experience of treatment in four siblings. Lancet 1985, 1:430-432.
22. Wallace C, Couch R, Ginsberg J: Fetal thyrotoxicosis: a case report and recommendations for prediction, diagnosis, and treatment Thyroid 1995, 5:125-128. A case report illustrating the pitfalls in the diagnosis and management of fetal hyperthyroidism in which treatment based on fetal heart rate resulted in hypothyroidism at birth. Current recommendations for diagnosis and treatment of fetal hyperthyroidism are reviewed along with recent developments in the field.
23. Wenstrom KD, Weiner CP, Williamson RA, Grant SS: Prenatal diagnosis of fetal hyperthyroidism using funipuncture. Obstet Gynecol 1990, 76:513-517.
24. Daneman D, Howard NJ: Neonatal thyrotoxicosis: intellectual impairment and craniosynostosis in later years. J Pediatr 1980, 97:257-259.
25. Mandel SH, Hanna CE, LaFranchi SH: Diminished thyroid-stimulating hormone secretion associated with neonatal thyrotoxicosis. J Pediatr 1986, 109:662-665.
26. Hashimoto H, Maruyama H, Koshida R, Okuda N, Sato T: Central hypothyroidism resulting from pituitary suppression and peripheral thyrotoxicosis in a premature infant born to a mother with Graves' disease. J Pediatr 1995, 127:809-811. Confirms previous reports of central hypothyroidism following neonatal thyrotoxicosis and relates the development of hypothyroidism to the sequential changes in thyroid-stimulating hormone receptor antibodies.
27. Barnes H, Blizzard RM: Antithyroid drug therapy for toxic diffuse goiter (Graves' disease): thirty years experience in children and adolescents. J Pediatr 1977, 91:313-320.
28. Vaidya VA, Bongiovanni AM, Parks JS, Tenore A, Kirkland RT: Twenty-two years' experience in the medical management of juvenile thyrotoxicosis. Pediatrics 1974, 54:565-570.
29. Kogut MD, Kaplan SA, Collip PJ, Tiamsic T, Boyle D: Treatment of hyperthyroidism in children. N Engl J Med 1965, 272:217-221.
30. Friedman JM, Fialkow PJ: The genetics of Graves' disease. J Clin Endocrinol Metab 1978, 7:47-65.
31. Lavard L, Perrild H, Jacobsen B, Madsen HO, Svetjgaard: Unique HLA class association in juvenile Graves. Thyroid 1995, 5(suppl 1):S147.
32. Manglkabruks A, Cox N, DeGroot LJ: Genetic factor in autoimmune thyroid disease analyzed by restriction fragment length polymorphism of candidate genes. J Clin Endocrinol Metab 1991, 73:236-244.
33. DeGroot LJ, Quintans J: The causes of autoimmune thyroid disease. Endocr Rev 1989, 10:537-562.
34. Wall JR, Hayes M, Scalise D, Stolarski C, Nebes V, Kiljanski J, Salvi M, Sato M: Native gel electrophoresis and isolelectric focusing of a 64- kilodalton eye muscle protein shows that it is an important target for serum autoantibodies in patients with thyroid-associated ophthalmopathy and not expressed in other skeletal muscle. J Clin Endocrinol Metab 1995, 80:1226-1232.
35. Bahn RS, Heufelder AE: Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993, 329:1468-1475.
36. Cavallo A, Casta A, Fawcett HD, Nusynowitz ML, Wolf WJ: Is there a thyrotoxic cardiomyopathy in children? J Pediatr 1985, 107:531-536.
37. Radetti G, Dordi B, Mengarda G, Biscaldi I, Larizza D, Seven F: Thyrotoxicosis presenting with seizures and coma in two children. Am J Dis Child 1993, 147:925-926.
38. Wakasugi M, Wakao R, Tawata M, Gan N, Inoue M, Koizumi K, Onaya T: Change in bone mineral density in patients with hyperthyroidism after attainment of euthyroidism by dual energy X-ray absorptiometry. Thyroid 1994, 5:179-182.
39. Foley TP Jr, White C, New A: Juvenile Graves' disease: usefulness and limitations of thyrotropin receptor antibody determinations. J Pediatr 1987, 110:378-386.
40. McKenzie JM, Zakarija M: The clinical use of thyrotropin receptor antibody measurements. J Clin Endocrinol Metab 1989, 69:1093-1096.
41. Franklyn JA: The management of hyperthyroidism. N Engl J Med 1994, 330:1731-1738. An excellent recent review of the diagnosis and treatment of the various forms of hyperthyroidism, although oriented mostly to adults. The author describes the advantages and disadvantages of antithyroid drug therapy, radioiodine treatment, and surgery for Graves' disease. Management of hyperthyroidism associated with thyroiditis, toxic adenomas, and toxic nodular goiters is also discussed.
42. Perrild H, Gruters-Kieslich A, Feldt-Rasmussen U, Grant D, Martino E, Kayser L, Delange F: Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol 1994, 131:467-473.
43. Totterman TH, Karlsson FA, Bengtsson M, Mendel-Hartrig I: Induction of circulating activated suppressor-like T cells by methimazole therapy for Graves' disease. N Engl J Med 1987, 316:15-22.
44. 2, and heat shock protein, their action is explained by the effect of reduced thyroid hormone concentrations within the thyroid gland without a need to invoke a direct immunosuppressive effect.
45. Okuno A, Yano K, Inyaku F, Suzuki Y, Sanaø N, Kumai M, Naitoh Y: Pharmacokinetics of methimazole in children and adolescents with Graves' disease. Studies on plasma and intrathyroidal concentrations. Acta Endocrinol (Copenh) 1987, 115:112-118.
46. Buckingham BA, Costin G, Roe TF, Weitzman JJ, Kogut MD: Hyperthyroidism in children. A reevaluation of treatment. Am J Dis Child 1981, 135:112-117.
47. Gorton C, Sadeghi-Nejad A, Senior B: Remission in children with hyperthyroidism treated with propylthlouracil. Long-term results. Am J Dis Child 1987, 141:1084-1086.
48. Hamburger JI: Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985, 60:1019-1024.
49. Lippe BM, Landau EM, Kaplan SA: Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987, 64:1241-1245.
50. Maenpaa J, Kuusi A: Childhood hyperthyroidism. Results of treatment. Acta Paediatr Scand 1980, 69:137-142.
51. Siok-Hoon T, Bee-wah L, Hock-Boon W, Uma R: Relapse markers in childhood thyrotoxicosis. Clin Pediatr 1987, 26:136-139.
52. Hashizume K, Ichikawa K, Sakurai A, Suzuki S, Takeda T, Kobayashi M, Miyamoto T, Arai M, Nagasawa T: Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med 1991, 324:947-953.
53. Kuo S-W, Huang W-S, Hu C-A, Liao W-K, Fung T-C, Wu S-Y: Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid therapy. Eur J Endocrinol 1994, 131:125-130. This study from Taiwan reported a fall in TRSAb level from 38% to 10% in the methimazole combined with thyroxine group, with no fall in TRSAb in the methimazole alone group. Thyroid volume treated by ultrasound correlated with the serum TRSAb level.
54. Tamai H, Hayaki I, Kawai K, Komaki G, Matsubayashi S, Kuma K, Kumagai LF, Nagataki S: Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab 1995, 80:1481-1484. This group from Japan reported that thyroxine administration in combination with methimazole, as compared with methimazole administration alone, had no effect on the levels of antibodies to thyrotropin receptors and no effect on the rate of recurrence of hyperthyroidism.
55. Tamai H, KasaqiK, Takaichi Y, Takamatsu J, Komaki G, Matsubayashi S, Konishi J, Kuma K, Kumagai LF, Nagataki S: Development of spontaneous hypothyroidism in patients with Graves' disease treated with antithyroid drugs: clinical, immunological, and histological findings in 26 patients. J Clin Endocrinol Metab 1989, 69:49-53.
56. Levy WJ, Schumacher P, Gupta M: Treatment of childhood Graves' disease. A review with emphasis on radiolodine treatment Cleve Clin J Med 1988, 55:373-382.
57. Clark JD, Gelfand MJ, Elgazzar AH: Iodine-131 therapy of hyperthyroidism in pediatric patients. J Nucl Med 1995, 36:442-445. This study reported that radioiodine (average, 7.7 mCi) was effective treatment in a group of 35 hyperthyroid children. Five patients required a second treatment dose. Eighty-three percent became hypothyroid within 100 days.
58. Safa AM, Schumacher OP, Rodriguez-Antunez A: Long-term follow-up results in children and adolescents treated with radioactive iodine for hyperthyroidism. N Engl J Med 1975, 292:167-171.
59. Dobyns BM, Sheline GE, Workman JB, Tompkins EA, McConahey WM, Becker DV: Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974, 38:976-998.
60. Hall P, Boice JD Jr, Berg G, Bjelkengren G, Ericsson U-B, Hallquist A, Lidberg M, Lundell G, Mattsson A, Tennvall J, Wiklund K, Holm L-E: Leukaemia incidence after iodine-131 exposure. Lancet 1992, 340:1-4.
61. Andrassy RJ, Buckingham BA, Weitzman JJ: Thyroidectomy for hyperthyroidism in children. J Pediatr Surg 1980, 15:501-504.
62. Hayles AB, Chaves-Carballo E, McConahey WM: The treatment of hyperthyroidism (Graves' disease) in children. Mayo Clin Proc 1967, 42:218-224.
63. Zimmerman D, Gan-Gaisano M: Hyperthyroidism in children and adolescents. Pediatr Clin North Am 1990, 37:1273-1295.
64. Porcellini A, Ilaria C, Laviola L, Amabile G, Fenzi G, Awedimento VE: Novel mutations of thyrotropin receptor gene in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1994, 79:657-661. In a group of 11 patients with hyperfunctioning thyroid adenomas, seven had mutations in the thyrotropin receptor, all in the sixth transmembrane domain.
65. Takeshita A, Nagayama Y, Yokoyama N, Ishikawa N, Ho K, Yamashita T, Obara T, Murakami Y, Kuma K, Takamatsu J, Ohsawa N, Nagaataki S: Rarity of oncogneic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. J Clin Endocrinol Metab 1995, 80:2607-2611.
66. Russo D, Arturi F, Wicker R, Chazenbalk GD, Schlumberger M, DuVillard J-A D, Caillou B, Monier R, Rapaport B, Filetti S, Suarez HG: Genetic alterations in thyroid hyperfunctioning adenomas. J Clin Endocrinol Metab 1995, 80:1347-1351. In a group of 37 patients with hyperfunctioning thyroid adenomas, three had point mutations in the thyrotropin receptor (all in the third intracellular loop), nine had mutations in the alpha subunit of the G protein, and one had a ras-activating mutation.
67. Lee PA, Van Dop C, Migeon CJ: McCune-Albright syndrome. Long-term follow-up. JAMA 1986, 256:2980-2984.
68. Refetoff A, Weiss RE, Usala SJ: The syndromes of resistance to thyroid hormone. Endocr Rev 1993, 14:348-399.
69. Hedberg CW, Fishbein DB, Jaussen RS, Meyers B, McMillen JM, MacDonald KL, White KE, Huss LT, Aurwitz ES, Fashie JR, Simmons JL, Braverman LE, Ingbar SH, Schonbergar LB, Osterholm MT: An outbreak of thyrotoxicosis caused by the consumption of bovine thyroid gland in ground beef. N Engl J Med 1987, 316:993-998.